Exact Sciences reported fourth‑quarter revenue of $878.4 million, a 23% year‑over‑year increase driven by growth in its cancer‑screening business and precision oncology testing. CEO Kevin Conroy highlighted product momentum and portfolio expansion as reasons for optimism. The company is moving toward a special shareholder vote on Feb. 20 to approve Abbott Laboratories’ proposed $23 billion acquisition. Exact’s accelerating screening revenues and narrowing net losses frame the deal as a strategic consolidation in diagnostics; shareholders will weigh near‑term financial performance against long‑term integration risks.